PHGE - Biomx Inc
NYSE * Health Care * Biotechnology
$1.84
$-0.13 (-6.60%)
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
PHGE Key Statistics
Market Cap
$12.89M
P/B Ratio
19.39
EPS
$-37.05
Employees
20
How PHGE Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Biomx Inc Company Information
- Headquarters
- New York; U.S.A
- Website
- www.biomx.com
- Sector
- Health Care
- Industry
- Biotechnology